Fiduciary Trust Co Sells 1,062 Shares of Moderna, Inc. (NASDAQ:MRNA)

Fiduciary Trust Co lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 0.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 161,983 shares of the company’s stock after selling 1,062 shares during the quarter. Fiduciary Trust Co’s holdings in Moderna were worth $10,825,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in MRNA. Lazard Asset Management LLC increased its position in Moderna by 81.4% in the 1st quarter. Lazard Asset Management LLC now owns 10,171 shares of the company’s stock worth $1,082,000 after buying an additional 4,563 shares during the period. B. Riley Wealth Advisors Inc. grew its stake in shares of Moderna by 18.6% in the first quarter. B. Riley Wealth Advisors Inc. now owns 9,871 shares of the company’s stock worth $1,020,000 after acquiring an additional 1,549 shares during the last quarter. iA Global Asset Management Inc. increased its position in Moderna by 4.7% during the first quarter. iA Global Asset Management Inc. now owns 35,900 shares of the company’s stock worth $3,826,000 after acquiring an additional 1,609 shares during the period. LRI Investments LLC acquired a new position in Moderna during the 1st quarter valued at $124,000. Finally, Swedbank AB bought a new stake in Moderna in the 1st quarter valued at $3,315,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MRNA. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and lowered their price target for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. TD Cowen decreased their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. The Goldman Sachs Group cut their target price on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a research report on Thursday, September 19th. Finally, Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $83.26.

Moderna Trading Up 3.2 %

MRNA opened at $43.39 on Thursday. The stock has a market capitalization of $16.70 billion, a price-to-earnings ratio of -7.46 and a beta of 1.69. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The company has a 50-day simple moving average of $53.32 and a 200 day simple moving average of $92.28.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.39) EPS. Analysts predict that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 1,147 shares of company stock valued at $76,245. 15.70% of the stock is currently owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.